U.S. Markets closed

Waters Corporation (NYSE: WAT) Reports Third Quarter 2019 Financial Results

MILFORD, Mass.--(BUSINESS WIRE)--

  • Sales of $577 million were flat as reported and grew 1% in constant currency
  • Pharmaceutical growth of 3%, partially offset by other end markets
  • Continued growth in Asia, with weakness in the Americas
  • GAAP EPS of $2.07; non-GAAP EPS of $2.13, an 11% increase from prior year

Waters Corporation (WAT) today announced third quarter 2019 sales of $577 million, which were flat as reported, compared to sales of $578 million for the third quarter of 2018. Foreign currency translation negatively impacted sales growth by approximately 1% for the quarter.

On a GAAP basis, diluted earnings per share (EPS) for the third quarter of 2019 increased to $2.07, compared to $1.83 for the third quarter of 2018. On a non-GAAP basis, EPS increased to $2.13, compared to $1.92 for the third quarter of 2018. A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company’s website at http://www.waters.com under the caption “Investors.”

On a GAAP basis, net cash provided by operating activities was $148 million for the third quarter of 2019, compared to $146 million for the third quarter of 2018. On a non-GAAP basis, adjusted free cash flow for the third quarter of 2019 was $124 million versus $136 million for the third quarter of 2018.

For the first nine months of 2019, the Company’s sales were $1,690 million, a decrease of 1% as reported, compared to sales of $1,705 million for the first nine months of 2018. Foreign currency translation negatively impacted sales growth by approximately 2% for the nine months of 2019.

On a GAAP basis, EPS for the first nine months of 2019 increased to $5.63, compared to $5.21 for the first nine months of 2018. On a non-GAAP basis, EPS increased to $5.85, compared to $5.45 in the first nine months of 2018.

On a GAAP basis, net cash provided by operating activities was $451 million for the first nine months of 2019, compared to $423 million for the first nine months of 2018. On a non-GAAP basis, adjusted free cash flow for the first nine months of 2019 was $418 million versus $439 million for the first nine months of 2018.

“Third quarter revenue came in lighter than we expected due to unanticipated late-quarter softness in the U.S., while the rest of our business performed largely as planned,” commented Chris O’Connell, Chairman and Chief Executive Officer of Waters Corporation. “Despite the macro challenges we’ve faced, 2019 has been an important year for new product launches that we expect will provide increasing sales contributions over the coming quarters and years.”

Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis and are the same as the sales growth and decline percentages presented on a constant-currency basis as compared with the same period in the prior year, each of which is detailed in the reconciliation of sales growth rates to constant-currency growth rates in the tables below.

During the third quarter of 2019, sales into the pharmaceutical market increased 1% as reported and 3% in constant currency, sales into the industrial market were flat, and sales into the academic and governmental markets declined 4% as reported and 3% in constant currency. For the first nine months of 2019, sales into the pharmaceutical market were flat as reported and grew 3% in constant currency, sales into the industrial market declined 3% as reported and 2% in constant currency, and sales into the academic and governmental markets declined 2% as reported and were flat in constant currency.

During the third quarter, recurring revenues, which represent the combination of service and precision chemistries revenues, grew 4% as reported and 5% in constant currency, while instrument system sales declined 4% as reported and 3% in constant currency. For the first nine months of 2019, recurring revenues grew 2% as reported and 4% in constant currency, while instrument system sales declined 4% as reported and 3% in constant currency.

Geographically, sales in Asia during the quarter grew 7%, sales in the Americas declined 5% (with U.S. sales declining 4%), and sales in Europe declined 4% as reported and were flat in constant currency. For the first nine months of 2019, sales in Asia increased 3% as reported and 4% in constant currency, sales in the Americas were flat (with U.S. sales growing 2%), and sales in Europe declined 7% as reported and 2% in constant currency.

Fourth Quarter and Fiscal Year 2019 Financial Outlook

The Company expects fourth quarter 2019 constant-currency sales growth in the range of 0% to 2%. As of today, currency translation is expected to decrease fourth quarter sales growth by one percentage point. The Company also expects fourth quarter 2019 non-GAAP EPS in the range of $2.95 to $3.05. Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the fourth quarter.

In addition, the Company is updating its previously issued full-year guidance, and currently expects full-year 2019 constant-currency sales growth to be approximately 1%, compared to the prior range of 1% to 3%. As of today, currency translation is expected to decrease full-year sales growth by approximately one to two percentage points. The Company also expects full-year 2019 non-GAAP EPS in the range of $8.73 to $8.83, compared to our prior range of $8.95 to $9.10. Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full year.

Conference Call

Waters Corporation will webcast its third quarter 2019 financial results conference call today, October 29, 2019 at 8:00 a.m. Eastern Time. To listen to the call, please visit www.waters.com, choose “Investors,” and click on the “Live Webcast.” A replay will be available through November 5, 2019 at midnight Eastern Time on the same website by webcast and also by phone at 402-998-0587.

About Waters Corporation

Waters Corporation (WAT), the world's leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With approximately 7,200 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.

Non-GAAP Financial Measures

This press release contains financial measures, such as constant-currency growth rate, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered “non-GAAP” financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Waters Corporation’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Waters Corporation’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Cautionary Statement

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects”, and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, foreign exchange rate fluctuations potentially affecting translation of the Company’s future non-U.S. operating results; the impact on demand for the Company’s products among the Company’s various market sectors or geographies from economic, sovereign and political uncertainties, particularly regarding the effect of new or proposed tariff or trade regulations or changes in the interpretation or enforcement of existing regulations; the effect on the Company’s financial results from the United Kingdom voting to exit the European Union; fluctuations in expenditures by the Company’s customers, in particular large pharmaceutical companies; introduction of competing products by other companies and loss of market share; pressures on prices from competitors and/or customers; regulatory, economic and competitive obstacles to new product introductions; other changes in demand for the Company’s products from the effect of mergers and acquisitions by the Company’s customers; increased regulatory burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others; impact of the newly enacted tax reform legislation in the U.S.; shifts in taxable income in jurisdictions with different effective tax rates; the outcome of tax examinations or changes in respective country legislation affecting the Company’s effective tax rate; the effect of the adoption of new accounting standards; the ability to access capital, maintain liquidity and service the Company’s debt in volatile market conditions, particularly in the U.S., as a large portion of the Company’s cash is held and operating cash flows are generated outside the U.S.; environmental and logistical obstacles affecting the distribution of products and risks associated with lawsuits and other legal actions, particularly involving claims for infringement of patents and other intellectual property rights. Such factors and others are discussed more fully in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K/A for the year ended December 31, 2018 as filed with the Securities and Exchange Commission, which “Forward-Looking Statements” and “Risk Factors” discussions are incorporated by reference in this release. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

 
Waters Corporation and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
 
 
Three Months Ended Nine Months Ended
September 28,
2019
September 29,
2018
September 28,
2019
September 29,
2018
 
Net sales

$

577,278

 

$

578,021

 

$

1,690,302

 

$

1,704,910

 

 
Costs and operating expenses:
Cost of sales

 

241,055

 

 

241,139

 

 

711,632

 

 

705,695

 

Selling and administrative expenses

 

126,036

 

 

126,997

 

 

393,583

 

 

394,049

 

Research and development expenses

 

34,333

 

 

35,173

 

 

105,883

 

 

105,297

 

Purchased intangibles amortization

 

2,619

 

 

2,114

 

 

7,164

 

 

5,375

 

Litigation provision (settlement)

 

-

 

 

924

 

 

-

 

 

(748

)

 
Operating income

 

173,235

 

 

171,674

 

 

472,040

 

 

495,242

 

 
Other expense

 

(496

)

 

(811

)

 

(1,363

)

 

(2,293

)

Interest expense, net

 

(8,001

)

 

(1,633

)

 

(16,826

)

 

(8,609

)

 
Income from operations before income taxes

 

164,738

 

 

169,230

 

 

453,851

 

 

484,340

 

 
Provision for income taxes(a)

 

26,605

 

 

28,216

 

 

62,322

 

 

75,698

 

 
Net income

$

138,133

 

$

141,014

 

$

391,529

 

$

408,642

 

 
 
Net income per basic common share

$

2.09

 

$

1.84

 

$

5.68

 

$

5.26

 

 
Weighted-average number of basic common shares

 

66,226

 

 

76,575

 

 

68,952

 

 

77,741

 

 
 
Net income per diluted common share

$

2.07

 

$

1.83

 

$

5.63

 

$

5.21

 

 
Weighted-average number of diluted common shares and equivalents

 

66,768

 

 

77,136

 

 

69,533

 

 

78,395

 

 
(a) The provision for income taxes for the nine months ended September 28, 2019 included a $3 million benefit related to the finalization of tax regulations under tax reform during the first quarter of 2019. The provision for income taxes for the three and nine months September 28, 2018 included a $2 million expense and a $6 million expense, respectively, related to the tax on the change in foreign currency exchange rates on the earnings taxed in December 31, 2017 under the Tax Cuts and Jobs Act. The difference is due to the change from the foreign currency exchange rates required by the U.S. Department of the Treasury on December 31, 2017 to the foreign currency exchange rates on either the date of distribution of assets into the U.S. or the foreign currency exchange rates as of September 28, 2019 and September 29, 2018, respectively.
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP
Net Sales by Operating Segment, Products & Services, Geography and Markets
Three Months Ended September 28, 2019 and September 29, 2018
(In thousands)
Current
Period Constant
Three Months Ended Percent Currency Currency
September 28, 2019 September 29, 2018 Change Impact Growth Rate (a)
 
NET SALES - OPERATING SEGMENT
 
Waters

$

 

512,146

$

 

515,795

(1

%)

$

 

(6,063

)

-

 

TA

65,132

62,226

5

%

(407

)

5

%

 
Total

$

 

577,278

$

 

578,021

-

 

$

 

(6,470

)

1

%

 
 
NET SALES - PRODUCTS & SERVICES
 
Instruments

$

 

270,317

$

 

282,543

(4

%)

$

 

(2,870

)

(3

%)

 
Service

206,705

199,499

4

%

(2,303

)

5

%

Chemistry

100,256

95,979

4

%

(1,297

)

6

%

Total Recurring

306,961

295,478

4

%

(3,600

)

5

%

 
Total

$

 

577,278

$

 

578,021

-

 

$

 

(6,470

)

1

%

 
 
NET SALES - GEOGRAPHY
 
Asia

$

 

237,775

$

 

222,196

7

%

$

 

(106

)

7

%

Americas

196,458

206,803

(5

%)

(160

)

(5

%)

Europe

143,045

149,022

(4

%)

(6,204

)

-

 

 
Total

$

 

577,278

$

 

578,021

-

 

$

 

(6,470

)

1

%

 
 
NET SALES - MARKETS
 
Pharmaceutical

$

 

328,227

$

 

325,166

1

%

$

 

(5,403

)

3

%

Industrial

171,352

171,985

-

 

(699

)

-

 

Academic & Governmental

77,699

80,870

(4

%)

(368

)

(3

%)

 
Total

$

 

577,278

$

 

578,021

-

 

$

 

(6,470

)

1

%

 
 
 
(a) The Company believes that referring to comparable constant-currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant-currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP
Net Sales by Operating Segment, Products & Services, Geography and Markets
Nine Months Ended September 28, 2019 and September 29, 2018
(In thousands)
Current
Period Constant
Nine Months Ended Percent Currency Currency
September 28, 2019 September 29, 2018 Change Impact Growth Rate (a)
 
NET SALES - OPERATING SEGMENT
 
Waters

$

 

1,503,177

$

 

1,514,246

(1

%)

$

 

(29,665

)

1

%

TA

187,125

190,664

(2

%)

(2,044

)

(1

%)

 
Total

$

 

1,690,302

$

 

1,704,910

(1

%)

$

 

(31,709

)

1

%

 
 
NET SALES - PRODUCTS & SERVICES
 
Instruments

$

 

778,540

$

 

812,690

(4

%)

$

 

(11,693

)

(3

%)

 
Service

611,961

598,402

2

%

(13,141

)

4

%

Chemistry

299,801

293,818

2

%

(6,875

)

4

%

Total Recurring

911,762

892,220

2

%

(20,016

)

4

%

 
Total

$

 

1,690,302

$

 

1,704,910

(1

%)

$

 

(31,709

)

1

%

 
 
NET SALES - GEOGRAPHY
 
Asia

$

 

677,122

$

 

659,381

3

%

$

 

(9,303

)

4

%

Americas

585,101

586,639

-

 

(1,015

)

-

 

Europe

428,079

458,890

(7

%)

(21,391

)

(2

%)

 
Total

$

 

1,690,302

$

 

1,704,910

(1

%)

$

 

(31,709

)

1

%

 
 
NET SALES - MARKETS
 
Pharmaceutical

$

 

972,884

$

 

968,848

-

 

$

 

(23,467

)

3

%

Industrial

502,679

$

 

517,979

(3

%)

$

 

(5,319

)

(2

%)

Academic & Governmental

214,739

$

 

218,083

(2

%)

$

 

(2,923

)

-

 

 
Total

$

 

1,690,302

$

 

1,704,910

(1

%)

$

 

(31,709

)

1

%

 
 
 
(a) The Company believes that referring to comparable constant-currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant-currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.
null
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP Financials
Three & Nine Months Ended September 28, 2019 and September 29, 2018
(In thousands, except per share data)
 
Income from
Operations
Selling & Operating Other before Provision for Diluted
Administrative Operating Income (Expense) Income Income Net Earnings
Expenses(a) Income Percentage Income Taxes Taxes Income per Share
Three Months Ended September 28, 2019
GAAP

$

 

128,655

 

$

 

173,235

 

30.0

%

$

 

(496

)

$

 

164,738

 

$

 

26,605

 

$

 

138,133

 

$

 

2.07

 

Adjustments:
Purchased intangibles amortization (b)

(2,619

)

2,619

 

0.5

%

-

 

2,619

 

535

 

2,084

 

0.03

 

Restructuring costs and certain other items (c)

(1,596

)

1,596

 

0.3

%

-

 

1,596

 

350

 

1,246

 

0.02

 

Certain income tax items (d)

-

 

-

 

-

 

-

 

-

 

(600

)

600

 

0.01

 

Adjusted Non-GAAP

$

 

124,440

 

$

 

177,450

 

30.7

%

$

 

(496

)

$

 

168,953

 

$

 

26,890

 

$

 

142,063

 

$

 

2.13